[DERM] Dermira, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 30.57 Change: 0.63 (2.1%)
Ext. hours: Change: 0 (0%)

chart DERM

Refresh chart

Strongest Trends Summary For DERM

DERM is in the medium-term down -51% below S&P in 1 year. In the long-term down -85% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-17.27% ROE-20.31% ROI
Current Ratio10.38 Quick Ratio Long Term Debt/Equity0.02 Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40 K Cash From Investing Activities1.86 M Cash From Operating Activities-5.12 M Gross Profit
Net Profit-14.04 M Operating Profit-14.23 M Total Assets165.61 M Total Current Assets124.49 M
Total Current Liabilities12 M Total Debt1.94 M Total Liabilities24.75 M Total Revenue
Technical Data
High 52 week14.82 Low 52 week5.31 Last close5.31 Last change0%
RSI18.73 Average true range0.46 Beta1.1 Volume98.87 K
Simple moving average 20 days-18.35% Simple moving average 50 days-30.51% Simple moving average 200 days-40.72%
Performance Data
Performance Week-7.17% Performance Month-40.67% Performance Quart-38.04% Performance Half-55.27%
Performance Year-54.54% Performance Year-to-date-26.15% Volatility daily3.7% Volatility weekly8.28%
Volatility monthly16.97% Volatility yearly58.78% Relative Volume231.19% Average Volume645.15 K
New High New Low

News

2020-02-23 17:23:01 | Largest Insider Trades of the Week

2020-02-20 08:55:00 | Lilly Completes Acquisition of Dermira

2020-02-07 13:04:15 | DERM Alert: Johnson Fistel Continues Investigation of Proposed Sale of Dermira, Inc. for $19.30

2020-02-05 13:30:00 | INVESTOR ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - LOGM, DERM, HXL

2020-02-04 20:00:10 | CSFL, DLPH, DERM, and HXL SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

2020-01-30 14:20:00 | SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - HXL, DERM, HABT

2020-01-30 10:38:03 | Lilly LLY Q4 Earnings and Sales Top Estimates, Stock Up

2020-01-30 10:08:15 | Eli Lilly beats profit estimates on strong demand for diabetes drug Trulicity

2020-01-30 09:59:47 | SHAREHOLDER ALERT: WeissLaw LLP Reminds CBB, HABT, DERM, and MFSF Shareholders About Its Ongoing Investigations

2020-01-29 19:26:00 | Lifshitz & Miller LLP Announces Investigation of AquaVenture Holdings Limited, CenterState Bank Corporation, Dermira, Inc., The Habit Restaurants, Inc., Hexcel Corporation, LogMeIn, Inc., Telaria, Inc, and TiVo Corporation

2020-01-29 12:33:39 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – HABT, DERM, HXL, PRMW

2020-01-28 20:00:10 | PRMW, DERM, HABT, and HXL SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

2020-01-27 08:16:01 | Lilly LLY to Report Q4 Earnings: What's in the Cards?

2020-01-24 16:46:53 | SHAREHOLDER ALERT: WeissLaw LLP Reminds HABT, DERM, and MFSF Shareholders About Its Ongoing Investigations

2020-01-20 11:15:00 | MERGER ALERT - INST, DERM, and PRMW: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

2020-01-20 09:00:10 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – CBB, HABT, DERM, IBKC

2020-01-16 18:23:54 | Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO

2020-01-15 21:00:10 | DERM, CRCM, LOGM, and WAAS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

2020-01-15 13:19:00 | Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Dermira, Primo Water, Hexcel, and Pope Resources on behalf of Stockholders and Encourages Investors to Contact the Firm

2020-01-15 11:16:00 | Moore Kuehn, PLLC Encourages PRMW, DERM, CBB, and HABT Investors to Contact Firm

2020-01-14 11:13:00 | Big Merger Deals Are Missing at Health Conference. Here’s Why.

2020-01-13 18:48:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Dermira, Inc. - Nasdaq:DERM

2020-01-13 12:33:31 | Biotech Stocks Slip on Lack of Deals at JPMorgan Conference

2020-01-13 11:30:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dermira, Inc. to Eli Lilly and Company is Fair to Shareholders

2020-01-13 09:08:02 | Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate

2020-01-11 09:30:00 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - CBB, HABT, DERM

2020-01-10 18:00:38 | Biotechs punch up talking points leading into big Union Square conference

2020-01-10 16:33:00 | Eli Lilly Made a Deal for Dermira. The Biotech’s Stock Price Shows Investors Expect More.

2020-01-10 15:23:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Dermira, Inc.

2020-01-10 13:23:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of DERMIRA, INC. - DERM

2020-01-10 13:10:00 | DERMIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2020-01-10 12:28:24 | DERMIRA MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dermira, Inc. is Fair to Shareholders; Investors are Encouraged to Contact the Firm – DERM

2020-01-10 12:13:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc.

2020-01-10 10:43:55 | Eli Lilly to add eczema drug with $1.1 billion deal for Dermira

2020-01-10 10:43:07 | Eli Lilly, Apple, Yum! Brands, Nintendo: Companies to watch

2020-01-10 09:50:00 | Lilly Says It’s Buying a Biotech With a Dermatitis Drug. Investors Have Other Ideas.

2020-01-10 09:33:02 | The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

2020-01-10 09:03:08 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR

2020-01-10 08:35:00 | DERM Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price?

2020-01-10 07:28:30 | Eli Lilly Reports Deal To Buy Dermira For $1.1B

2020-01-10 06:42:00 | Eli Lilly to buy Dermira in a deal valued at $1.1 billion

2020-01-10 06:30:00 | Lilly Announces Agreement to Acquire Dermira

2020-01-10 04:44:00 | Eli Lilly to Buy Skin Treatment Company Dermira for $1.1 Billion

2020-01-10 03:38:00 | Pre-market Movers - Eli Lilley, Boeing in View

2020-01-09 06:19:11 | Buy Multibagger Stocks as Odds of a Rally Are High in 2020

2020-01-08 11:16:04 | Pacira's PCRX Exparel Meets Key Goals in C-Section Study

2020-01-06 10:00:03 | Moving Average Crossover Alert: Dermira

2020-01-06 07:31:12 | Will Dermira Continue to Surge Higher?

2019-12-19 17:51:03 | 4 More Biotechs With Blockbuster Potential

2019-12-10 16:05:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4